These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
364 related items for PubMed ID: 10935991
1. Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice. Tracy S, Höfling K, Pirruccello S, Lane PH, Reyna SM, Gauntt CJ. J Med Virol; 2000 Sep; 62(1):70-81. PubMed ID: 10935991 [Abstract] [Full Text] [Related]
2. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Pinkert S, Pryshliak M, Pappritz K, Knoch K, Hazini A, Dieringer B, Schaar K, Dong F, Hinze L, Lin J, Lassner D, Klopfleisch R, Solimena M, Tschöpe C, Kaya Z, El-Shafeey M, Beling A, Kurreck J, Van Linthout S, Klingel K, Fechner H. Cardiovasc Res; 2020 Aug 01; 116(10):1756-1766. PubMed ID: 31598635 [Abstract] [Full Text] [Related]
3. Characterization of an infectious cDNA copy of the genome of a naturally occurring, avirulent coxsackievirus B3 clinical isolate. Lee CK, Kono K, Haas E, Kim KS, Drescher KM, Chapman NM, Tracy S. J Gen Virol; 2005 Jan 01; 86(Pt 1):197-210. PubMed ID: 15604447 [Abstract] [Full Text] [Related]
4. Secondary heterotypic versus homotypic infection by Coxsackie B group viruses: impact on early and late histopathological lesions and virus genome prominence. Yu JZ, Wilson JE, Wood SM, Kandolf R, Klingel K, Yang D, McManus BM. Cardiovasc Pathol; 1999 Jan 01; 8(2):93-102. PubMed ID: 10724506 [Abstract] [Full Text] [Related]
5. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. Tracy S, Drescher KM, Chapman NM, Kim KS, Carson SD, Pirruccello S, Lane PH, Romero JR, Leser JS. J Virol; 2002 Dec 01; 76(23):12097-111. PubMed ID: 12414951 [Abstract] [Full Text] [Related]
6. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region. Dunn JJ, Chapman NM, Tracy S, Romero JR. J Virol; 2000 May 01; 74(10):4787-94. PubMed ID: 10775617 [Abstract] [Full Text] [Related]
8. Coxsackievirus B3 induces apoptosis in the early phase of murine myocarditis: a comparative analysis of cardiovirulent and noncardiovirulent strains. Joo CH, Hong HN, Kim EO, Im JO, Yoon SY, Ye JS, Moon MS, Kim D, Lee H, Kim YK. Intervirology; 2003 Mar 01; 46(3):135-40. PubMed ID: 12867750 [Abstract] [Full Text] [Related]
9. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5' nontranslated region. Tu Z, Chapman NM, Hufnagel G, Tracy S, Romero JR, Barry WH, Zhao L, Currey K, Shapiro B. J Virol; 1995 Aug 01; 69(8):4607-18. PubMed ID: 7609025 [Abstract] [Full Text] [Related]
10. Strains of coxsackie virus B4 differed in their ability to induce acute pancreatitis and the responses were negatively correlated to glucose tolerance. Hindersson M, Orn A, Harris RA, Frisk G. Arch Virol; 2004 Oct 01; 149(10):1985-2000. PubMed ID: 15669109 [Abstract] [Full Text] [Related]
11. Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3. Zhang H, Yousef GE, Ouyang X, Archard LC. Int J Exp Pathol; 1994 Apr 01; 75(2):99-110. PubMed ID: 8199011 [Abstract] [Full Text] [Related]
12. A non-cardiovirulent strain of coxsackievirus B3 causes myocarditis in mice with severe combined immunodeficiency syndrome. Hufnagel G, Chapman N, Tracy S. Eur Heart J; 1995 Dec 01; 16 Suppl O():18-9. PubMed ID: 8682092 [Abstract] [Full Text] [Related]
13. The natural history of CVB3 myocarditis in C57BL/6J mice: an extended in-depth characterization. Favere K, Van Hecke M, Eens S, Bosman M, Stobbelaar K, Hotterbeekx A, Kumar-Singh S, L Delputte P, Fransen E, De Sutter J, Guns PJ, Roskams T, Heidbuchel H. Cardiovasc Pathol; 2024 Dec 01; 72():107652. PubMed ID: 38750778 [Abstract] [Full Text] [Related]
14. Group B coxsackievirus virulence. Tracy S, Gauntt C. Curr Top Microbiol Immunol; 2008 Dec 01; 323():49-63. PubMed ID: 18357765 [Abstract] [Full Text] [Related]
15. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Zhang H, Morgan-Capner P, Latif N, Pandolfino YA, Fan W, Dunn MJ, Archard LC. Am J Pathol; 1997 Jun 01; 150(6):2197-207. PubMed ID: 9176409 [Abstract] [Full Text] [Related]
16. Experimental CVB3-induced chronic myocarditis in two murine strains: evidence of interrelationships between virus replication and myocardial damage in persistent cardiac infection. Andréoletti L, Hober D, Becquart P, Belaich S, Copin MC, Lambert V, Wattré P. J Med Virol; 1997 Jun 01; 52(2):206-14. PubMed ID: 9179770 [Abstract] [Full Text] [Related]
17. Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy. Pinkert S, Dieringer B, Klopfleisch R, Savvatis K, Van Linthout S, Pryshliak M, Tschöpe C, Klingel K, Kurreck J, Beling A, Fechner H. Circ Heart Fail; 2019 Nov 01; 12(11):e005250. PubMed ID: 31718319 [Abstract] [Full Text] [Related]
18. Genetics of coxsackievirus B3 cardiovirulence. Tracy S, Tu Z, Chapman N, Hufnagel G. Eur Heart J; 1995 Dec 01; 16 Suppl O():15-7. PubMed ID: 8682085 [Abstract] [Full Text] [Related]